JP2023509441A - トファシチニブおよびフィンゴリモドを含む局所組成物 - Google Patents

トファシチニブおよびフィンゴリモドを含む局所組成物 Download PDF

Info

Publication number
JP2023509441A
JP2023509441A JP2022540904A JP2022540904A JP2023509441A JP 2023509441 A JP2023509441 A JP 2023509441A JP 2022540904 A JP2022540904 A JP 2022540904A JP 2022540904 A JP2022540904 A JP 2022540904A JP 2023509441 A JP2023509441 A JP 2023509441A
Authority
JP
Japan
Prior art keywords
composition
weight
tofacitinib
topical composition
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022540904A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023509441A5 (cg-RX-API-DMAC7.html
Inventor
エリオット,ラッセル
ハゾット,ヨハン
ウインクル,ガレス
マルグリス,アリエル
Original Assignee
バイン セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイン セラピューティクス インコーポレイテッド filed Critical バイン セラピューティクス インコーポレイテッド
Publication of JP2023509441A publication Critical patent/JP2023509441A/ja
Publication of JP2023509441A5 publication Critical patent/JP2023509441A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022540904A 2019-12-31 2020-12-31 トファシチニブおよびフィンゴリモドを含む局所組成物 Pending JP2023509441A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962955847P 2019-12-31 2019-12-31
US62/955,847 2019-12-31
US202063066717P 2020-08-17 2020-08-17
US63/066,717 2020-08-17
US202063086442P 2020-10-01 2020-10-01
US202063086275P 2020-10-01 2020-10-01
US63/086,275 2020-10-01
US63/086,442 2020-10-01
PCT/US2020/067612 WO2021138525A1 (en) 2019-12-31 2020-12-31 Topical composition comprising tofacitinib and fingolimod

Publications (2)

Publication Number Publication Date
JP2023509441A true JP2023509441A (ja) 2023-03-08
JP2023509441A5 JP2023509441A5 (cg-RX-API-DMAC7.html) 2024-01-17

Family

ID=74285586

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022540904A Pending JP2023509441A (ja) 2019-12-31 2020-12-31 トファシチニブおよびフィンゴリモドを含む局所組成物

Country Status (9)

Country Link
US (1) US20230037905A1 (cg-RX-API-DMAC7.html)
EP (1) EP4084776A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023509441A (cg-RX-API-DMAC7.html)
AU (1) AU2020417290A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022012917A2 (cg-RX-API-DMAC7.html)
CA (1) CA3163530A1 (cg-RX-API-DMAC7.html)
IL (1) IL294239A (cg-RX-API-DMAC7.html)
TW (1) TW202135825A (cg-RX-API-DMAC7.html)
WO (1) WO2021138525A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010302350B2 (en) 2009-10-02 2015-06-18 Journey Medical Corporation Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US12661407B2 (en) 2010-04-08 2026-06-23 Journey Medical Corporation Compositions, gels and foams with rheology modulators and uses thereof
JP7324210B2 (ja) * 2018-01-31 2023-08-09 ティダブリューアイ・バイオテクノロジー・インコーポレイテッド トファシチニブを含む局所製剤
CN116437921A (zh) * 2020-09-28 2023-07-14 株式会社Lg化学 鞘氨醇-1-磷酸酯受体激动剂的用途
CN120168480A (zh) * 2025-04-17 2025-06-20 四川省医学科学院·四川省人民医院 托法替尼在制备治疗干性年龄相关性黄斑变性的药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4874794A (en) 1989-04-28 1989-10-17 Lidak Biopharmaceuticals Inflammatory disease treatment
US9474720B2 (en) 2013-11-04 2016-10-25 BioPharmX, Inc. Dosage form comprising an active ingredient and a plurality of solid porous microcarriers

Also Published As

Publication number Publication date
CA3163530A1 (en) 2021-07-08
BR112022012917A2 (pt) 2022-09-06
EP4084776A1 (en) 2022-11-09
WO2021138525A1 (en) 2021-07-08
IL294239A (en) 2022-08-01
TW202135825A (zh) 2021-10-01
AU2020417290A1 (en) 2022-05-26
US20230037905A1 (en) 2023-02-09

Similar Documents

Publication Publication Date Title
JP7664358B2 (ja) 水混和性の薬学的に許容可能な溶媒の水性ブレンド中のロフルミラストの医薬組成物
TWI240635B (en) Active vitamin D3 emulsion lotion
AU2010302350B2 (en) Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
JP7847143B2 (ja) 皮膚疾患の治療のためのビタミンd類似体を有するjak阻害剤
US20230037905A1 (en) Topical composition comprising tofacitinib and fingolimod
US20200022912A1 (en) Non Surface Active Agent Non Polymeric Agent Hydro-Alcoholic Foamable Compositions, Breakable Foams And Their Uses
US20180235984A1 (en) Tetracycline management of egfr inhibitor associated dermatoses
US20240325393A1 (en) Tofacitinib-containing anhydrous elastomer-based gel formulations
EP3439632B1 (en) Topical composition comprising tacrolimus
KR20090084898A (ko) 비타민 d 유도체를 포함하는 연고 조성물
JP2020505469A (ja) 治療用アプレミラスト局所組成物
JP2022525221A (ja) 洗い流し組成物および活性剤を送達するためのそれらの使用
AU2010335655B2 (en) Calcipotriol monohydrate nanocrystals
JP2022501314A (ja) 局所用組成物
US20250339409A1 (en) Uses of pan bet inhibitors
AU2022399851A1 (en) Topical formulations of ruxolitinib with an organic amine ph adjusting agent for treatment of skin diseases
CN115554243A (zh) 一种治疗玫瑰痤疮的米诺环素泡沫剂
CN117157080A (zh) 用于治疗皮肤病的含维生素d类似物的jak抑制剂
US20250073251A1 (en) Compositions and methods and uses thereof
WO2024220589A2 (en) Uses of pan bet inhibitors cross-reference to related applications
US20230320984A1 (en) Tofacitinib-containing anhydrous elastomer-based gel formulations
JP4060347B2 (ja) 22−オキサ−1α,25−ジヒドロキシビタミンD3を含有する水中油型乳剤性ローション剤
WO2007086582A1 (ja) 22-オキサ-1α,25-ジヒドロキシビタミンD3を含有する水中油型乳剤性ローション剤およびそれを用いた皮膚疾患の治療方法
JP4965884B2 (ja) 吉草酸酢酸プレドニゾロンを含有するo/w型乳化製剤
JP5507600B2 (ja) 吉草酸酢酸プレドニゾロンを含有するo/w型乳化製剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231228